Cipla Limited 

(Public, BOM:500087)   Watch this stock   
Find more results for 500087
Jan 28, 2010
Q3 09/2010 CIPLA LTD Earnings Release
  

Key stats and ratios

Q4 (Dec '09) 2009
Net profit margin 19.85% 14.48%
Operating margin 23.87% 16.81%
EBITD margin - 20.28%
Return on average assets - 12.25%
Return on average equity - 19.03%

Address

Mumbai Central
Mumbai, 400 008
India
+91-22-23025272 (Phone)
+91-22-23008101 (Fax)

Website links

Cipla Limited discussions

  View all discussions »

Description

Cipla Limited is an Indian-based pharmaceutical company. The Company is focused on developing new drug formulations for existing and active drug substances. During the fiscal year ended March 31, 2009, the Company launched many new drugs and formulations, which include Abamune L (abacavir and lamivudine tablets), a nucleoside reverse transcriptase inhibitor (NRTI) combination for human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS); Aprepit (aprepitant capsules), a antiemetic for prevention of nausea and vomiting in cancer chemotherapy; Cold Spray (azelastine and budesonide spray), a combination spray for allergic rhinitis; Corvela (ranolazine tablets), a antianginal and antischaemic agent; Crisanta LS (drosperinone and ethinyl estradiol tablets), a oral contraceptive pill, and Desirox (deferasirox tablets), an iron chelator for thalassaemia.

Officers and directors

Y. K. Hamied
Executive Chairman of the Board, Managing Director
Mital Sanghvi
Compliance Officer, Secretary
Amar Lulla
Joint Managing Director, Executive Director
M. K. Hamied
Joint Managing Director, Executive Director
V. C. Kotwal
Independent Non-Executive Director
H. R. Manchanda
Independent Non-Executive Director
S. A.A. Pinto
Independent Non-Executive Director
Ramesh Shroff
Independent Non-Executive Director
M. R. Raghavan
Independent Non-Executive Director